16 maj: Onsdagens aktier: GN taget lidt til nåde i mildere C25
17 maj: NKT/Goldman: Sænker kursmål 20 kr
16-05-2018 23:00:07

Bavarian Nordic Announces Acceptance of Abstracts and Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting

Relateret indhold
17:04 - 
Torsdagens aktier: Pandora og Ørsted trak C25 i rødt
11:39 - 
Aktier/middag: Pandora og Ørsted trækker C25 i rødt
09:29 - 
Aktier/åbning: Ørsted og Pandora får tæsk i negativ C25..
Relateret debat
17:11 - 
Hvorfor skulle den ikke holde i morgen?
17:01 - 
Prostvac som mono terapi er død men ikke n&oslas..
16:19 - 
SYnes du det er svært at spå om 400 nå..

COPENHAGEN, Denmark, May 16, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced the acceptance of 4 poster presentations and one podium presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting held June 1-5, 2018 in Chicago Illinois. These abstracts are now publicly available online at https://meetinglibrary.asco.org/.

"We are very proud to participate in ASCO, the pre-eminent oncology meeting of the year. We look forward to sharing our progress with the medical community. This includes our phase 3 study of PROSTVAC, which while disappointing in its result, will still provide a number of academic and clinical learnings to the treatment field of prostate cancer, including the advancements in overall survival seen by current standards of care" said Paul Chaplin, President and CEO of Bavarian Nordic. 

"Importantly, the additional posters accepted at ASCO may provide insights into our future development strategies. One study demonstrates the ability of PROSTVAC to drive increased numbers of T cells into newly diagnosed prostate cancer. Another study demonstrated that PROSTVAC combined with nivolumab is safe and has adequate clinical data in advanced metastatic castration resistant prostate cancer to proceed to the planned evaluation of this combination in the neoadjuvant setting of newly diagnosed disease, in cooperation with National Cancer Institute and Bristol-Myers Squibb," Dr. Chaplin concluded.

Presentation and Poster Titles are as follows:

  • Effect of rilimogene galvacirepvec/rilimogene glafolivec (PROSTVAC) on intra/peritumoral immune infiltrate in patients with localized prostate cancer undergoing radical prostatectomy. (Abstract number 5083)

    Poster Session: Genitourinary (Prostate) Cancer. June 2, 2018 from 1:15PM - 4:45PM CDT

  • Combination of a therapeutic cancer vaccine (PROSTVAC) and immune checkpoint inhibitors in prostate cancer. (Abstract number 5084)

    Poster Session: Genitourinary (Prostate) Cancer. June 2, 2018 from 1:15 PM - 4:45 PM CDT

  • A trial of CV301 in combination with anti-PD-1 therapy versus anti-PD-1 therapy in subjects with non-small cell lung cancer. (Abstract number TPS9108)

    Poster Session: Lung Cancer-Non-Small Cell Metastatic. June 3, 2018 from 8:00AM -11:30AM CDT

  • A sequential cohort study of combination immunotherapy with BN-brachyury vaccine, M7824, ALT-803 and epacadostat in metastatic castration-resistant prostate cancer (mCRPC) (QuEST1). (Abstract number TPS3130)

    Poster Session: Developmental Therapeutics - Immunotherapy. June 4, 2018 from 8:00AM-11:30AM CDT

  • Results of PROSPECT: A randomized phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer. (Abstract number 5006)

    Oral Abstract Session: Genitourinary (Prostate) Cancer. June 4, 2018 from 3:00 PM-6:00 PM CDT

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development of innovative and safe therapies against cancer and infectious diseases. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates intended to improve the health and quality of life for children and adults. We supply our IMVAMUNE® non-replicating smallpox vaccine to the U.S. Strategic National Stockpile and other government stockpiles. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Registration studies are currently underway in the U.S. In addition to our long-standing collaboration with the U.S. government on the development of IMVAMUNE® and other medical countermeasures, our infectious disease pipeline comprises a proprietary RSV program as well as vaccine candidates for Ebola, HPV, HBV and HIV, which are developed through a strategic partnership with Janssen. Additionally, in collaboration with the National Cancer Institute, we have developed a portfolio of active cancer immunotherapies, designed to alter the disease course by eliciting a robust and broad anti-cancer immune response while maintaining a favorable risk-benefit profile. Through multiple industry collaborations, we seek to explore the potential synergies of combining our immunotherapies with other immune-modulating agents, e.g. checkpoint inhibitors.

For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.

Contacts

Rolf Sass Sørensen

Vice President Investor Relations (EU)

Tel: +45 61 77 47 43

Seth Lewis

Vice President Investor Relations (US)

Tel: +1 978 341 5271

Press Release

2018-05-16-en


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bavarian Nordic A/S via Globenewswire

Vedhæftet fil: 2018-05-16-en.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
18 maj
BAVA
Som lovet ville jeg vende tilbage i kurs 210. Tillykke til alle. Jeg holder. Kurs 250-260 kommer sna..
9
18 maj
BAVA
jeg tror den stiger når USA åbner, der er flere gode nyheder
6
20 maj
BAVA
Jeg har forøget kraftig i 180 og 170, jeg sælger ikke på dette niveau. Selvfølldig vilnjeg gerne hav..
5
18 maj
BAVA
Vi hæver i dag anbefalingen på Bavarian Nordic til Køb fra Hold med kursmål DKK 290. Det svarer til ..
5
14:28
BAVA
Vi er ved spørgsmål nu.. de forventer 120 mio USD for beviseret på Kopper...
4
11:17
BAVA
Jeg hæfter mig specielt ved, at han omkring 3:30 nævner, at der også er godt nyt i kulissen, som han..
4
09:11
BAVA
Jammen det er da utroligt - deres resultat er det som de har lovet markedet også er I nogle som kriv..
4
22 maj
BAVA
Shorterne kaster aktien - de får den ikke ned i 150 som de håbede. Kurs 220-225 er lige om hjørnet, ..
4
20 maj
BAVA
"The WHO is sending 7,540 doses of the vaccine developed by Merck to Congo. It is also in talks abou..
4
14:30
BAVA
Der er dialog med WHO om at bruge Janssen/Bavarians produkt ved Ebola..
3

Hartmann Q1: Sætter gang i effektiviseringsprogram for at nå 2018-mål

24-05-2018 14:29:06
Fremgang i emballagesalget og et højere teknologisalg prægede årets første kvartal hos emballageproducenten Brødrene Hartmann, der kom ud af perioden med en stigning i både omsætningen og indtjeningen.I første kvartal omsatte virksomheden for 624 mio. kr. mod 572 mio. kr. i samme periode af 2017, og fremgangen kom, på trods af at valutakurser påvirkede omsætningen i år med 55 mio. kr. Det fremgår ..

Pandora/Carnegie: Ser nedjustering komme senere på året

24-05-2018 09:59:22
Smykkekoncernen Pandora har kurs mod en nedjustering senere på året, vurderer Carnegie, som skærer gevaldigt i kursmålet for aktie til 400 kr. fra før 700 kr. og sænker anbefalingen til "sælg" fra "hold". Finanshusets Pandora-analytiker, Lars Topholm, peger også på, at det kan blive nødvendigt at få nye kræfter ind til at få gennemført de nødvendige ændringer i selskabet og genskabe tilliden. Regn..

TCM: Kapitalfond har solgt alle aktier seks måneder efter børsnotering

24-05-2018 08:35:40
Majoritetsaktionæren Innovator International, der ejes af kapitalfonden IK Investment Partners, har solgt alle sine aktier i den danske køkkenkoncern TCM Group.Salget af de i alt 1,97 mio. aktier er solgt gennem en accelereret bookbuiding-proces til institutionelle investorer for 98 kr. per aktie, skriver Bloomberg News.Torsdag er det præcist seks måneder siden, at TCM Group havde første handelsda..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Pandora/Carnegie: Ser nedjustering komme senere på året
2
Bavarian Q1: Lav omsætning giver trecifret millionunderskud
3
Pandora/Carnegie: Sænker anbefalingen til "sælg" fra "hold" - NY
4
Aktier/tendens: Ørsted kan blive presset af nederlag i USA
5
Norwegian suser til vejrs efter historie om Ryanair-interesse

Relaterede aktiekurser

Bavarian Nordic A/S 209,30 1,7% Stigning i aktiekurs
Bavarian Nordic Ord Shs 206,80 0,4% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Cookie- og privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
24. maj 2018 17:24:44
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180515.2 - EUROWEB3 - 2018-05-24 17:24:44 - 2018-05-24 17:24:44 - 1 - Website: OKAY